Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948943 | 0.85 | HCAR3 (0.59) | MAPTHCAR3HTTCDC25BKMT2A | |
| SCHEMBL13948941 | 0.83 | HCAR3 (0.50) | MAPTHCAR3HTTCDC25BLMNA | |
| SCHEMBL9947020 | 0.83 | HCAR3 (0.47) | MAPTCYP3A4BLMPMP22HCAR3 | |
| SCHEMBL13680344 | 0.82 | HCAR3 (0.49) | MAPTHCAR3HTTCDC25BLMNA | |
| SCHEMBL10981845 | 0.80 | HCAR3 (0.55) | MAPTHCAR3HTTCDC25BLMNA | |
| SCHEMBL5827232 | 0.78 | MAPT (0.58) | MAPTCYP3A4BLMPMP22LMNA | |
| SCHEMBL7216360 | 0.77 | MAPT (0.57) | MAPTCYP3A4BLMPMP22HTT | |
| SCHEMBL15264994 | 0.77 | MAPT (0.60) | MAPTCYP3A4BLMPMP22LMNA | |
| SCHEMBL29995429 | 0.77 | MAPT (0.60) | MAPTCYP3A4BLMPMP22LMNA | |
| SCHEMBL7370622 | 0.76 | MAPT (0.56) | MAPTCYP3A4LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2650286-A1 | Quinazoline derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8404698-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404698-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20090030021-A1 | Quinazoline Derivatives and Therapeutic Use Thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030021-A1 | Quinazoline Derivatives and Therapeutic Use Thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-7388014-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388014-B2 | Quinazoline derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030021-A1 | Quinazoline Derivatives and Therapeutic Use Thereof | ABL1, NQO2, NRAS | MAPT 3928/4885CYP3A4 1087/4885BLM 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.